Prognostic value of clinicopathological parameters in adenoid cystic carcinoma: A retrospective cohort study

Figure 1 No significant differences in overall survival or disease-free survival were observed with respect to age, sex, nodal status, or receipt of adjuvant chemotherapy. A: Overall survival (OS) by T stage. Patients with early-stage tumors (T1 and T2) showed significantly better OS than those with advanced disease (T3 and T4) (median OS: 88.4 months vs 48.2 months; log-rank χ² = 6.17, P = 0.013); B: OS by surgical margin status. Negative margins were associated with improved OS compared with positive margins (median OS: 84.7 months vs 39.6 months; χ² = 4.65, P = 0.031); C: OS by postoperative radiotherapy (PORT). PORT was associated with longer survival (median OS not reached vs 51.4 months without PORT; χ² = 4.18, P = 0.041); D: Disease-free survival (DFS) by T stage. Advanced tumors (T3 and T4) had significantly shorter DFS than early-stage tumors (T1 and T2) (median DFS: 36.7 months vs 82.1 months; χ² = 6.82, P = 0.009); E: DFS by margin status. Positive margins were associated with earlier recurrence (median DFS: 38.4 months vs 80.5 months; χ² = 4.89, P = 0.027); F: DFS by PORT. PORT significantly prolonged DFS compared with no PORT (median DFS not reached vs 45.2 months; χ² = 4.06, P = 0.044). DFS: Disease-free survival; OS: Overall survival; PORT: Postoperative radiotherapy.